UICC study group on basic and clinical cancer research: Genotypes and phenotypes of tumor suppressors
β Scribed by Arnold J. Levine; Max M. Burger
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- French
- Weight
- 301 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
It is the purpose of these Study Group Meetings, which are organized by the UICC Tumor Biology Program, to establish a basis for possible clinical applications founded on molecular concepts. For this purpose a few clinicians, pathologists and epidemiologists are regularly invited to the meetings, which are of a particularly informal nature, to foster the exchange of ideas rather than data. It is for this reason that no book is published as a follow-up but rather the following short report. More detailed data can be requested from the participants directly. Their addresses are provided at the end.
The last meeting (Burger and Croce, 1990) dealt primarily with the retinoblastoma (pRB) tumor-suppressing gene and its product. This meeting provides a follow-up on pRB but deals primarily with p53.
'This meeting was sponsored by CIBA, Basel, Switzerland. The Tumor Biology Program of UICC (Dr. R. Brentani) and the participants express their gratitude for the unselfish support and low-key presence of the sponsor.
π SIMILAR VOLUMES
Cancer-suppressing systems have been considered by pathologists and oncologists alike over the last 3 decades, and for several years immune surveillance was in the lime-light. Cancer-suppressing genes, however, have only recently been pinpointed in the aftermath of the bustle of activity set off by
The first study group meeting in biological and clinical cancer research, sponsored by the Tumor Biology Program of the UICC and devoted to metastasis, was held in Annapolis, USA, on September 25-28,1983. Such study groups will provide a forum for basic cancer research workers on the one hand, and p
It is the purpose of these Study Group Meetings, which are organized by the Tumor Biology Program of the UICC, to establish a basis for possible clinical applications founded on molecular conce ts. For this purpose, a few clinicians, 'This meeting was sponsored hy Ciha AG, Basel, Switzcrland. The Tu